N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide

C47H50N10O8 — CID 138728192

IUPACN-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide
SMILESCN(CCCCCCCCCc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(=O)c1ccc(-n2cc(NC(=O)c3coc(-c4ccnc(NCC5CC5)c4)n3)c(C(N)=O)n2)cc1
InChIInChI=1S/C47H50N10O8/c1-55(23-8-6-4-2-3-5-7-10-29-11-9-12-33-39(29)47(64)57(46(33)63)36-19-20-38(58)53-43(36)61)45(62)30-15-17-32(18-16-30)56-26-34(40(54-56)41(48)59)51-42(60)35-27-65-44(52-35)31-21-22-49-37(24-31)50-25-28-13-14-28/h9,11-12,15-18,21-22,24,26-28,36H,2-8,10,13-14,19-20,23,25H2,1H3,(H2,48,59)(H,49,50)(H,51,60)(H,53,58,61)
InChIKeyZHKBOMMYLWDDIY-UHFFFAOYSA-N
MW882.98 g/mol
LogP5.54
Rot. Bonds20

About N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide

N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide (PubChem CID 138728192) has the molecular formula C47H50N10O8 and a molecular weight of 882.98 g/mol. Its IUPAC name is N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide.

Molecular Properties

Compound NameN-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide
PubChem CID138728192
Molecular FormulaC47H50N10O8
Molecular Weight882.98 g/mol
Exact Mass882.38
IUPAC NameN-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide
SMILESCN(CCCCCCCCCc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(=O)c1ccc(-n2cc(NC(=O)c3coc(-c4ccnc(NCC5CC5)c4)n3)c(C(N)=O)n2)cc1
InChIInChI=1S/C47H50N10O8/c1-55(23-8-6-4-2-3-5-7-10-29-11-9-12-33-39(29)47(64)57(46(33)63)36-19-20-38(58)53-43(36)61)45(62)30-15-17-32(18-16-30)56-26-34(40(54-56)41(48)59)51-42(60)35-27-65-44(52-35)31-21-22-49-37(24-31)50-25-28-13-14-28/h9,11-12,15-18,21-22,24,26-28,36H,2-8,10,13-14,19-20,23,25H2,1H3,(H2,48,59)(H,49,50)(H,51,60)(H,53,58,61)
InChIKeyZHKBOMMYLWDDIY-UHFFFAOYSA-N
XLogP5.54
TPSA244.82 Ų
H-Bond Donors4
H-Bond Acceptors13
Rotatable Bonds20
Heavy Atoms65
Complexity

Lipinski Rule of Five

3 violations

RuleValue
MW ≤ 500882.98
LogP ≤ 55.54
H-Bond Donors ≤ 54
H-Bond Acceptors ≤ 1013

Computed Properties (RDKit)

Structural Alerts{'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'phthalimide', 'substructure': 'N/A'}

Analyze N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

Frequently Asked Questions

What is the IUPAC name of N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide?
The IUPAC name of N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide (CID 138728192) is N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide.
What is the SMILES notation for N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide?
The canonical SMILES for N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide is CN(CCCCCCCCCc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)C(=O)c1ccc(-n2cc(NC(=O)c3coc(-c4ccnc(NCC5CC5)c4)n3)c(C(N)=O)n2)cc1.
What is the InChIKey of N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide?
The InChIKey is ZHKBOMMYLWDDIY-UHFFFAOYSA-N. The full InChI is InChI=1S/C47H50N10O8/c1-55(23-8-6-4-2-3-5-7-10-29-11-9-12-33-39(29)47(64)57(46(33)63)36-19-20-38(58)53-43(36)61)45(62)30-15-17-32(18-16-30)56-26-34(40(54-56)41(48)59)51-42(60)35-27-65-44(52-35)31-21-22-49-37(24-31)50-25-28-13-14-28/h9,11-12,15-18,21-22,24,26-28,36H,2-8,10,13-14,19-20,23,25H2,1H3,(H2,48,59)(H,49,50)(H,51,60)(H,53,58,61).
What are the key properties of N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide?
N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide has a molecular weight of 882.98 g/mol, XLogP of 5.54, 20 rotatable bonds, 4 hydrogen bond donors, and 13 hydrogen bond acceptors.
Where does this data come from?
All data for N-[3-carbamoyl-1-[4-[9-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]nonyl-methylcarbamoyl]phenyl]pyrazol-4-yl]-2-[2-(cyclopropylmethylamino)-4-pyridinyl]-1,3-oxazole-4-carboxamide is sourced from PubChem (CID 138728192), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).